Following the discovery of the four molecular subtypes of endometrial cancer (EC) by The
Cancer Genome Atlas (TCGA) in 2013, subsequent studies used surrogate markers to …

Advanced and recurrent gynecological cancers are associated with poor prognosis and lack
of effective treatment. The developments of the molecular mechanisms on cancer …

Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …

Highlights•This ESMO Clinical Practice Guideline provides key recommendations for
managing endometrial cancer.•The guideline covers clinical and pathological diagnosis …

PURPOSE Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment
of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic …

Endometrial Cancer Endometrial carcinoma is diagnosed in about 58,500 women in the
United States per year. It is linked with obesity, excess estrogen, and the Lynch syndrome …

Angiogenesis is required in cancer, including gynecological cancers, for the growth of
primary tumors and secondary metastases. Development of anti-angiogenesis therapy in …

Simple Summary In this review, we discuss the different treatment strategies in recurrent
endometrial cancer. The incidence of endometrial cancer is rising. The available treatment …

Background When determining adjuvant treatment for endometrial cancer, the decision
typically relies on factors such as cancer stage, histologic grade, subtype, and a few …